Strategic Partnerships Yuhan has active joint ventures and affiliations with global players such as Janssen, The Clorox Company, and Kimberly-Clark, plus contract manufacturing for active pharmaceutical ingredients. This indicates a strong preference for collaborate-to-grow models, suggesting sales opportunities in API supply, co-development, and cross-licensing arrangements with these and similar partners.

R&D Investment Significant year-to-date R&D spending with a notable rise in H1 2026 demonstrates a robust pipeline and potential near-term product launches. Sales outreach can target upcoming generics, specialty therapies, or drug candidates like YH35995 for Gaucher disease, aligning with BD efforts around early-access programs, clinical trial partnerships, and licensed manufacturing.

Expansion into Skincare Launch of The I Yu skincare brand and a dedicated cosmetics marketing subsidiary signal diversification into consumer health. There are opportunities to offer contract manufacturing, private-label partnerships, or ingredient sourcing for dermatology-focused consumer products and nutraceuticals that leverage Yuhan’s wellness positioning.

Contract & APIOpportunities Recent API supply contract with BridgeBio for cardiomyopathy treatment indicates active engagement in contract manufacturing and specialty APIs. Sales opportunities exist in expanding API supply for oncology, cardiovascular, and autoimmune therapies, as well as expansion into high-value niche APIs and toll manufacturing.

Regulatory & IP Leverage Orphan Drug Designations and favorable regulatory milestones, along with impactful IP/licensing matters from recent tax and transfer rulings, create openings for strategic collaborations around regulatory-enabled products, market-access support, and licensed production of niche therapies in Korea and globally.